Mrs Eileen Soulis
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Eileen.Soulis@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Eileen.Soulis@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
Heggie, R., Jaiswal, N. , McCartney, E. , Moss, J., Menne, T., Jones, B., Boyd, K. , Soulis, E., Hawkins, N. and Wu, O. (2023) Central venous access devices for the delivery of systemic anticancer therapy: an economic evaluation. Value in Health, (doi: 10.1016/j.jval.2023.09.2996) (PMID:37844662) (In Press)
Crabb, S. J. et al. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), pp. 54-64. (doi: 10.1200/JCO.22.00405) (PMID:35960902) (PMCID:PMC9788980)
Moss, J. G. et al. (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet, 398(10298), pp. 403-415. (doi: 10.1016/S0140-6736(21)00766-2) (PMID:34297997)
Wu, O. et al. (2021) Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment, 25(47), (doi: 10.3310/hta25470)
Fulton, B. et al. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, 344. (doi: 10.1186/s13063-020-04283-5) (PMID:32306987) (PMCID:PMC7168999)
Graham, J.S., Boyd, K. , Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, 161. (doi: 10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)
Heggie, R., Jaiswal, N. , McCartney, E. , Moss, J., Menne, T., Jones, B., Boyd, K. , Soulis, E., Hawkins, N. and Wu, O. (2023) Central venous access devices for the delivery of systemic anticancer therapy: an economic evaluation. Value in Health, (doi: 10.1016/j.jval.2023.09.2996) (PMID:37844662) (In Press)
Crabb, S. J. et al. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), pp. 54-64. (doi: 10.1200/JCO.22.00405) (PMID:35960902) (PMCID:PMC9788980)
Moss, J. G. et al. (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet, 398(10298), pp. 403-415. (doi: 10.1016/S0140-6736(21)00766-2) (PMID:34297997)
Wu, O. et al. (2021) Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment, 25(47), (doi: 10.3310/hta25470)
Fulton, B. et al. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, 344. (doi: 10.1186/s13063-020-04283-5) (PMID:32306987) (PMCID:PMC7168999)
Graham, J.S., Boyd, K. , Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, 161. (doi: 10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)